115 related articles for article (PubMed ID: 20238466)
21. Impact of first-line sildenafil monotreatment for pulmonary arterial hypertension.
Yanagisawa R; Kataoka M; Taguchi H; Kawakami T; Tamura Y; Fukuda K; Yoshino H; Satoh T
Circ J; 2012; 76(5):1245-52. PubMed ID: 22333215
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy of combination therapy with bosentan and sildenafil for refractory pulmonary arterial hypertension associated with fibrotic lung in systemic sclerosis].
Gocho K; Sugino K; Ota H; Kusano E; Takai Y; Homma S
Nihon Kokyuki Gakkai Zasshi; 2010 Oct; 48(10):786-90. PubMed ID: 21066870
[TBL] [Abstract][Full Text] [Related]
23. Therapy with sildenafil or bosentan decreases pulmonary vascular resistance in patients ineligible for heart transplantation because of severe pulmonary hypertension.
Perez-Villa F; Farrero M; Sionis A; Castel A; Roig E
J Heart Lung Transplant; 2010 Jul; 29(7):817-8. PubMed ID: 20363156
[No Abstract] [Full Text] [Related]
24. [Preliminary study on the efficacy and safety of oral sildenafil in pulmonary arterial hypertension in China].
Xiong CM; He JG; Lu XL; Shan GL; Wu BX; Zhu XY; Wu GH; Zeng XF; Guo T; Liu ZH; Ni XH; Cheng XS; Gu Q; Zhao ZH; Tian HY; Li WM; Zhang DZ; Zhang C; Li MT; Liu HM; Guo YJ; Shen JY; Zhang WJ; Liu S; Zhou DX; Bao CD; Huang SA; Chen JY; Wu WF; Huang K; Li CL; Wang LH; He B
Zhonghua Yi Xue Za Zhi; 2011 Feb; 91(6):370-4. PubMed ID: 21418907
[TBL] [Abstract][Full Text] [Related]
25. eComment. Further study needed.
Quraishi NN; Lemon TI; Black LF
Interact Cardiovasc Thorac Surg; 2013 Dec; 17(6):968. PubMed ID: 24243943
[No Abstract] [Full Text] [Related]
26. Oral sildenafil to control pulmonary hypertension after congenital heart surgery.
Peiravian F; Amirghofran AA; Borzouee M; Ajami GH; Sabri MR; Kolaee S
Asian Cardiovasc Thorac Ann; 2007 Apr; 15(2):113-7. PubMed ID: 17387192
[TBL] [Abstract][Full Text] [Related]
27. Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
Don GW; Joseph F; Celermajer DS; Corte TJ
Intern Med J; 2012 Dec; 42(12):1351-4. PubMed ID: 23253000
[TBL] [Abstract][Full Text] [Related]
28. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
[TBL] [Abstract][Full Text] [Related]
29. Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy.
Jacobs W; Boonstra A; Marcus JT; Postmus PE; Vonk-Noordegraaf A
J Heart Lung Transplant; 2009 Mar; 28(3):280-4. PubMed ID: 19285621
[TBL] [Abstract][Full Text] [Related]
30. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report.
Keogh A; Strange G; Kotlyar E; Williams T; Kilpatrick D; Macdonald P; Brown K; Pidoux A; Kermeen F; Steele P; Dalton B; Gabbay E
Intern Med J; 2011 Mar; 41(3):235-44. PubMed ID: 21118410
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers.
Spence R; Mandagere A; Dufton C; Venitz J
J Clin Pharmacol; 2008 Dec; 48(12):1451-9. PubMed ID: 18832294
[TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
[TBL] [Abstract][Full Text] [Related]
33. Combination of sildenafil and bosentan for pulmonary hypertension in a human ex vivo model.
Ried M; Potzger T; Neu R; Sziklavari Z; Szöke T; Liebold A; Hofmann HS; Hoenicka M
Cardiovasc Drugs Ther; 2014 Feb; 28(1):45-51. PubMed ID: 24193244
[TBL] [Abstract][Full Text] [Related]
34. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study.
Rubin LJ; Badesch DB; Fleming TR; Galiè N; Simonneau G; Ghofrani HA; Oakes M; Layton G; Serdarevic-Pehar M; McLaughlin VV; Barst RJ;
Chest; 2011 Nov; 140(5):1274-1283. PubMed ID: 21546436
[TBL] [Abstract][Full Text] [Related]
35. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension.
Barst RJ; Ivy DD; Gaitan G; Szatmari A; Rudzinski A; Garcia AE; Sastry BK; Pulido T; Layton GR; Serdarevic-Pehar M; Wessel DL
Circulation; 2012 Jan; 125(2):324-34. PubMed ID: 22128226
[TBL] [Abstract][Full Text] [Related]
36. Severe pulmonary arterial hypertension in a very premature baby with bronchopulmonary dysplasia: normalization with long-term sildenafil.
Caputo S; Furcolo G; Rabuano R; Basilicata AM; Pilla LM; De Simone A; Pasquariello B; Ciampi Q; Vetrano G; Villari B
J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):704-6. PubMed ID: 19829144
[TBL] [Abstract][Full Text] [Related]
37. Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: a retrospective cohort study.
Berger A; Edelsberg J; Teal S; Mychaskiw MA; Oster G
BMC Pulm Med; 2012 Dec; 12():75. PubMed ID: 23231890
[TBL] [Abstract][Full Text] [Related]
38. Role of ambrisentan in the management of pulmonary hypertension.
Hrometz SL; Shields KM
Ann Pharmacother; 2008 Nov; 42(11):1653-9. PubMed ID: 18957622
[TBL] [Abstract][Full Text] [Related]
39. How long can we leave patients with pulmonary arterial hypertension on oral drug monotreatment?
Ogawa A; Matsubara H
Circ J; 2012; 76(5):1089-90. PubMed ID: 22466634
[No Abstract] [Full Text] [Related]
40. [Oral sildenafil in neonatal medicine: ''tested in adults also used in neonates''].
Sola A; Baquero H
An Pediatr (Barc); 2007 Feb; 66(2):167-76. PubMed ID: 17306104
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
